Medscape | Idelalisib and rituximab extends survival in CLL patients The Oncology Report ... rituximab extends survival in CLL patients. Adding idelalisib to rituximab significantly extends survival in patients with heavily pretreated relapsed chronic lymphocytic leukemia unsuitable for chemotherapy, according to published results from ... Idelalisib Shows Efficacy in Relapsed CLL and Lymphoma |
